107 Elm Street
Stamford, CT 06902
Cara Therapeutics is a clinical stage biotechnology company focused on developing novel, superior therapeutics to treat pain and inflammation associated with diverse medical conditions. Cara’s pipeline includes drug candidates within several classes of peripherally-acting analgesics, along with a proprietary technology, GPCR DimerScreen™, for the discovery of innovative pain treatments based on novel pharmacological mechanisms
The Company’s lead drug development program encompasses peripherally-selective compounds that specifically activate kappa opioid receptors present on peripheral, pain-sensing nerves. Based on clinical studies conducted to date, and unlike currently marketed opioid receptor agonists, these new compounds have not demonstrated typical opiate side effects such as inhibition of intestinal transit (ileus), induction of life-threatening respiratory depression, or production of CNS side effects associated with euphoria or addiction.